Leerink Partnrs Has Pessimistic View of KPTI FY2025 Earnings

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Equities researchers at Leerink Partnrs decreased their FY2025 earnings per share estimates for shares of Karyopharm Therapeutics in a research note issued to investors on Wednesday, February 19th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings of ($0.75) per share for the year, down from their previous estimate of ($0.66). The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.71) per share.

Other analysts have also recently issued reports about the company. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday. Royal Bank of Canada reissued an “outperform” rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday. Piper Sandler boosted their price objective on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. Finally, StockNews.com lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Karyopharm Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Karyopharm Therapeutics Stock Down 1.9 %

Shares of KPTI opened at $0.60 on Monday. The business’s 50 day moving average price is $0.66 and its 200-day moving average price is $0.76. Karyopharm Therapeutics has a 52 week low of $0.53 and a 52 week high of $1.70. The stock has a market cap of $75.54 million, a P/E ratio of -0.59 and a beta of 0.06.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Wednesday, February 19th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.02. The firm had revenue of $30.54 million for the quarter, compared to the consensus estimate of $30.29 million.

Institutional Investors Weigh In On Karyopharm Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Velan Capital Investment Management LP purchased a new stake in Karyopharm Therapeutics during the 4th quarter valued at $27,000. Focus Partners Wealth purchased a new stake in Karyopharm Therapeutics during the 4th quarter valued at $31,000. TD Waterhouse Canada Inc. purchased a new stake in Karyopharm Therapeutics during the 4th quarter valued at $32,000. Two Sigma Advisers LP increased its stake in shares of Karyopharm Therapeutics by 145.5% in the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after purchasing an additional 45,400 shares in the last quarter. Finally, Opti Capital Management LP purchased a new stake in shares of Karyopharm Therapeutics in the 4th quarter worth $85,000. 66.44% of the stock is currently owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).